News

Company co-founded with Reza Foudazi, PhD, developer of a platform membrane technology with broad applications in bioprocessing and industrial filtration. > Read more

 

 

Startups are pulling outsized financing rounds and debt acquisitions at an unprecedented rate despite the high 80 percent failure rate of startups overall.> Read more

 

 

Can you tell us a little bit about your background and experience?

I was a founder and CEO of a pharmaceutical manufacturing company, and then took over and grew a nonprofit medical technology incubator, helping others to start and grow their own life science-based companies. Before all that, I had been a CPA and a partner in a worldwide consulting and accounting firm. > Read more

 

 

In the past year, VIC’s portfolio of companies reached numerous milestones, the VIC Investor Network (VIN) experienced its first exit, and we added important new elements to the VIC ecosystem. While progress in 2019 was excellent, 2020 looks even more promising. > Read more

 

 

Please start off by describing your current role with Biolocity and the organization’s unique model.

I am the Managing Director for Biolocity, which is a philanthropic, multi-institutional program that accelerates the commercialization of early-stage medical technologies with intellectual property held at Emory University and/or Georgia Institute of Technology.  > Read more

 

 

For decades, only venture capital (VC) firms, and very rarely, angels were able to invest in start-up companies developing life science—therapeutics, medical devices, diagnostics, and related—innovation.  Anyone doing so needed deep domain expertise to make heads or tails of what were typically fairly complex and esoteric concepts.  > Read more

 

 

Welcome to the 20s! To my ears, 2020 sounds very futuristic – but we are living it. The pace of technological change continues to accelerate and have profound impact on all of us. VIC’s motto is Technology Solutions for a Better World and the choices VIC makes in licensing new technologies reflect that motto.  > Read more

 

 

Ask ten people how best to assess the value of a new technology, and you’ll likely get ten different answers. Google “opportunity assessment”, and you will find hundreds of different templates, worksheets, and frameworks. Most of these start with some version of the same basic questions.  > Read more

 

 

Why Is Life Science Impact Investing So Crucial For Physicians Today?

A high paying role with a prestigious title in medicine is no longer enough. It’s not enough in many ways. The path of throwing yourself into research and digging through constant daily business challenges as an entrepreneur in the health space isn’t for everyone either.  > Read more

 

 

You are the Assistant Vice Chancellor & Managing Director for Technology Transfer at Washington University in St. Louis. Can you please tell us about your background and what drives your sense of purpose in technology transfer?

I have a background in Cell Biology, but when I was pursuing my doctorate, I found that bench work did not energize me the way it did for my fellow grad students. At the same time, however, I had the opportunity to work in the technology transfer office at the university and it enabled me to understand that I loved the big picture and the potential applications of research.  > Read more